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Although PARP inhibitors (PARPi) target homologous recombination defective tumours, drug
resistance frequently emerges, often via poorly understood mechanisms. Here, using
genome-wide and high-density CRISPR-Cas9 “tag-mutate-enrich” mutagenesis screens, we
identify close to full-length mutant forms of PARP1 that cause in vitro and in vivo PARPi
resistance. Mutations both within and outside of the PARP1 DNA-binding zinc-ﬁnger domains
cause PARPi resistance and alter PARP1 trapping, as does a PARP1 mutation found in a clinical
case of PARPi resistance. This reinforces the importance of trapped PARP1 as a cytotoxic
DNA lesion and suggests that PARP1 intramolecular interactions might inﬂuence PARPi-
mediated cytotoxicity. PARP1 mutations are also tolerated in cells with a pathogenic BRCA1
mutation where they result in distinct sensitivities to chemotherapeutic drugs compared to
other mechanisms of PARPi resistance (BRCA1 reversion, 53BP1, REV7 (MAD2L2) mutation),
suggesting that the underlying mechanism of PARPi resistance that emerges could inﬂuence
the success of subsequent therapies.
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Drugs targeting the poly-(ADP-ribose) polymerase (PARP)enzymes PARP1 and PARP2 cause synthetic lethality intumour cells with homologous recombination (HR)
defects, including those with loss-of-function mutations in the
BRCA1 or BRCA2 tumour suppressor genes1–3. PARP1 acts as a
DNA damage sensor, rapidly binding single- and double-stranded
DNA breaks as they occur and then coordinating their repair by
synthesising poly-(ADP-ribose) (PAR) chains on target proteins
(PARylation)4. The rationale for using PARP inhibitors (PARPi)
to treat HR-deﬁcient cancers is based on the exquisite sensitivity
of BRCA1- or BRCA2-defective cells to small-molecule PARPi, as
well as the ability of Parp1 gene silencing to selectively inhibit
Brca1- or Brca2-defective cells1, 2. Subsequent experiments have
revealed that in addition to inhibiting the catalytic activity of
PARP1, most clinical PARPi cause cytotoxicity by trapping
PARP1 at sites of DNA damage5–7, consistent with earlier
observations that PARP1 displays a greater afﬁnity for DNA
breaks in the presence of toolbox PARPi8, 9. The PARP1 trapping
potency of different inhibitors correlates with their cytotoxic
potency, with talazoparib (BMN673, Pﬁzer) showing the
greatest effect5, 6. Complete ablation of PARP1 expression by
transposon-mediated mutagenesis or gene silencing in BRCA1/
BRCA2 wild-type (WT) cells results in extreme resistance to
several PARPi1, 5–7.
The ability of some PARPi to trap PARP1 might be partially
explained by the observation that PARP1 DNA binding is
independent of its catalytic activity, while dissociation of
PARP1 from DNA requires PARylation10. Recent structural
studies have proposed a model of PARP1 binding to single-
stranded DNA damage that takes into account a series of
molecular interactions between different PARP1 protein
domains11–13. In its non-DNA-bound state, a regulatory
PARP1 helical domain (HD) is proposed to prevent catalytic
activity. Upon PARP1 DNA binding (via N-terminal zinc-ﬁn-
ger (ZnF) DNA-binding domains), an unfolding of the PARP1
helical region accompanies catalytic activation and
PARP1 synthesises PAR chains on itself and other acceptor
proteins in the vicinity11–13. These PARylation events recruit
other DNA repair enzymes, such as XRCC114, and act as a
second messenger signalling the presence of DNA damage. The
synthesis of highly negatively charged PAR chains on PARP1 is
thought to also cause dissociation of PARP1 from DNA, pre-
sumably through a steric mechanism10.
Here we used CRISPR-Cas9 mutagenesis to investigate the
mechanisms of PARPi toxicity in greater detail. We apply a
focused mutagenesis approach to generate a large number of
PARP1 mutant alleles that cause resistance, identifying an axis of
intramolecular communication in PARP1 that mediates PARPi
toxicity. We isolate PARP1 mutants from tumour cells with
BRCA1 exon 11 mutations and demonstrate that residual BRCA1
function in these cells allows tolerance of PARP1 loss of function,
despite the synthetic lethal relationship between these genes. A
PARP1 mutation observed in a tumour from a PARPi-resistant
patient prevents PARP1 trapping, suggesting that PARP1 muta-
tions that impair trapping could contribute to clinical PARPi
resistance. Finally, we ﬁnd that PARP1 mutations caused a dis-
tinct set of drug sensitivities when compared to other known
forms of PARPi resistance (loss of REV7 (MAD2L2) or TP53BP1,
or BRCA1 reversion mutants), suggesting that knowledge of the
molecular mechanism of resistance in individual patients could
inform decisions on further treatment.
Results
In-frame Parp1 deletions cause PARPi resistance. Although
PARPi are showing considerable promise as the ﬁrst of a new
generation of synthetic lethal therapies, resistance is a major
issue15, 16. To better understand this, we carried out a genome-
wide CRISPR-Cas9 mutagenesis screen (encompassing 87
897 single guide RNAs (sgRNAs)) to identify mouse embryonic
stem (ES) cell mutants resistant to the potent PARPi
talazoparib5, 17 (BMN673). We isolated and analysed 24 resistant
clones (Methods, Fig. 1a). Nine clones harboured one of two
different sgRNAs targeting Parp1 (Table 1). Parp1 was the only
gene that was targeted by more than one different sgRNA among
the resistant clones (Table 1 and Fig. 1b).
Parp1 protein was absent in all of the PARPi-resistant clones
with a Parp1 sgRNA (Fig. 1c) with one exception (clone BR8),
consistent with the observation that ablation of PARP1 expres-
sion prevents PARP1 trapping and causes PARPi resistance5, 7.
DNA sequencing of the Parp1 target site in clone BR8 revealed
two in-frame Parp1 mutations: c.127_129delATG and c.
[127_129delATG;130T>A] (p.43delM and p.[43delM;44F>I],
Fig. 1d). Both M43 and F44 residues are conserved between
human and mouse PARP1 proteins and are predicted to be
involved in base stacking interactions formed at the site of DNA/
PARP1 interaction by the ZnFs of the PARP1 DNA-binding
domain18. Using the PARP1 trapping assay6, we found that
mutant Parp1 protein was not associated with the chromatin (C)
fraction after talazoparib treatment, in contrast to the WT protein
(Fig. 1e), suggesting that Parp1 trapping was impaired. A PARP1-
GFP fusion protein with the p.[43delM;44F>I] mutation also
failed to be recruited to DNA damage produced by laser
microirradiation and did not produce PAR at the irradiated site,
as monitored by expression of a ﬂuorescent PAR-binding
reporter, PBZ-mRuby2 (Fig. 1f; Methods; and D.B.K. and C.J.
L., manuscript submitted). The magnitude of talazoparib
resistance in the BR8 mutant clone was similar to that seen in
Parp1 mutants that showed complete loss of Parp1 protein
expression, such as BR13 (Fig. 1g). The BR8 clone also exhibited
resistance to olaparib (Fig. 1h, p < 0.0001, analysis of variance
(ANOVA)), suggesting a drug class effect. We also noted that
Parp1 mutant ES cells exhibited enhanced sensitivity to
camptothecin, a topoisomerase I inhibitor (Supplementary
Figure 1a), consistent with previous observations19, 20. Taken
together, these observations suggested that loss of Parp1 DNA
binding and activity caused by mutations in the ZnF domain of
the protein can drive PARPi resistance.
Parp1-independent resistance to talazoparib. We sequenced the
Parp1 sgRNA target sites in all PARPi-resistant clones but only
identiﬁed Parp1 mutations in clones with a Parp1 sgRNA. We
therefore considered alternative explanations for PARPi resis-
tance in the other clones identiﬁed from the screen. Although
Parp1 was the only gene represented by multiple distinct sgRNAs
in the PARPi-resistant cells, the hallmark of a true positive screen
hit, we did identify multiple clones that carried either a sgRNA
targeting Tdg or a sgRNA targeting Trp53 (clones BR11, 14 and
24 for Tdg and BR5 and 21 for Trp53; Table 1). Tdg, which
encodes thymine DNA glycosylase, was unusual in that there was
only a single, rather than multiple, sgRNA design present in the
screening library. We therefore designed an additional sgRNA
(Supplementary Figure 1b) and generated independent Tdg-
defective clones, each of which conﬁrmed the PARPi resistance
phenotype associated with Tdg loss (Supplementary Figure 1c, d).
Tdgmutants exhibited WT sensitivity to camptothecin or ionising
radiation (Supplementary Figure 1a, e), and displayed WT Parp1
trapping characteristics in methyl methanesulfonate (MMS)-
treated cells (Supplementary Figure 1f), and thus did not phe-
nocopy Parp1 mutants. Tdg removes thymine, as well as some
modiﬁed uracil and cytosine, residues from DNA, thus creating
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abasic sites21. It seems possible that Tdg acts upstream of Parp1
to generate substrates for Parp1 trapping, and that in its absence,
a reduction in Parp1 trapping causes drug resistance, a hypothesis
previously suggested22. However, we were unable to detect a
profound general defect in Parp1 trapping in Tdg mutants
(Supplementary Figure 1f) suggesting that this phenotype might
be more mechanistically complex or undetectable using this
approach.
Further investigation of clones with guides targeting Trp53
(encoding the mouse homologue of p53) revealed that each had
the same compound frameshift mutations and were thus likely
sister clones (Supplementary Figure 1g). Sequencing of the ES cell
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library prior to selection revealed that all Trp53-targeting guides
were highly enriched in the pre-PARPi-exposed population of
cells (Supplementary Figure 1h). Although these clones did show
signiﬁcant talazoparib resistance (Supplementary Figure 1i, p <
0.0001, ANOVA), we would expect to have isolated more than
one Trp53 mutation event if this were a speciﬁc effect. It is
therefore likely that these clones were isolated due to their high
abundance in the pre-PARPi-exposed population.
A focused CRISPR-Cas9 screen for in-frame PARP1mutations.
Our CRISPR screens highlighted a key feature of CRISPR
mutagenesis—the ability to cause and easily identify subtle
mutations as well as null mutations, such as the p.43delM
mutation in the BR8 clone (Fig. 1d). To study such mutations in
more detail and to identify which regions of PARP1 are required
for PARPi cytotoxicity, we designed an experimental approach to
directly select PARPi-resistant cells with CRISPR-Cas9-induced
mutations that preserved the native PARP1 reading frame (e.g.,
in-frame insertion/deletion mutations, rather than frameshift
mutations that may cause production of truncated protein). This
approach, which we term “tag-mutate-enrich” (Fig. 2a), used
HeLa cells with a BAC transgene containing PARP1 gene fused to
green ﬂuorescent protein (GFP) coding sequence (encoding a
PARP1 protein with a C-terminal GFP fusion). The GFP tag
allowed us to enrich for cells with in-frame PARP1 protein
expression by ﬂuorescence-activated cell sorting (FACS) isolating
the GFP-positive fraction. PARP1-GFP cells were mutated with a
focused sgRNA library of 29 guide RNAs targeting PARP1
(Supplementary Data 1); PARPi-resistant cells were then selected
via talazoparib exposure and the GFP-positive fraction isolated
(Fig. 2a). The sgRNA library was introduced as six different
lentiviral pools, grouped by reverse transcription-PCR (RT-PCR)
product later used for genotyping. These products were ampliﬁed
from GFP cDNA and sequenced using the Ion Torrent PGM
platform (Fig. 2a). For all but one sgRNA pool we saw a sig-
niﬁcant enrichment of in-frame mutations in PARP1 in the
PARPi-resistant population (compared to a null hypothesis of 1/3
in-frame mutations; pools 1, 2, 4, 5 and 6: p < 10−15, binomial test
with alternative hypothesis p(success) > 1/3, 95% conﬁdence
interval (CI) 0.62–1.00. Pool 3, 95% CI 0.24–1.00, p= 1; Sup-
plementary Figure 2a). Most of these in-frame mutations were
close to a CRISPR target site (95% of indels, represented by 70%
of total reads, within 5 bp of a predicted target site, p < 1 × 10–5,
based on Monte Carlo simulation of a randomly occurring
mutation, Supplementary Figure 2b). By translating and aligning
in-frame reads from PGM sequencing, we identiﬁed candidate
PARP1 amino-acid residues associated with resistance. For
example, most reads from the PARPi-resistant population
generated from sgRNA pool 1 exhibited deletion of nucleotides
encoding amino-acid residues K119 and S120 (Fig. 2b and Sup-
plementary Figure 2a), which are both DNA-contacting residues
within the second ZnF domain of PARP118. We also observed
numerous other alleles with deletions or insertions affecting this
region (Fig. 2b and Supplementary Data 2 and 3). Our subsequent
microirradiation assay analysis demonstrated that a
p.119_120delKS mutation abolished PARP1-GFP recruitment to
the sites of DNA damage (Fig. 2c), suggesting that mutations in
residues K119 and S120 might cause PARPi resistance by altering
PARP1 DNA-binding properties.
Mutations outside the ZnF domains cause PARPi resistance.
The focused sgRNA screen also identiﬁed three PARP1 mutations
in residues not known to be directly involved in DNA binding:
p.329N>Q (N329Q); p.742-743HD>F (HD742F); and p.848delY
(848delY, Fig. 2d and Supplementary Data 2 and 3). N329 sits
within the third ZnF of PARP1, but is not predicted to form part
of the DNA-binding interface. HD742F is located within the HD,
a regulatory region shown to be important for PARP
activation11, 12. Y848 is part of a solvent-exposed helix of the
catalytic domain (Fig. 2d). In cell-free assays using recombinant
PARP1 proteins, we found the talazoparib IC50 to be similar for
mutant and WT PARP1 proteins (Supplementary Figure 2c, d),
suggesting that the PARPi resistance phenotypes were not caused
by differences in the ability of PARPi to inhibit the catalytic
activity of mutant proteins. PARP1 trapping assays in CAL51
PARP1–/– cells transfected with mutant or WT PARP1-GFP
cDNA expression constructs suggested that N329Q and HD742F
mutant proteins were not trapped by PARPi (Fig. 2e), explaining
the PARPi-resistant phenotypes associated with these mutations.
In contrast, PARP1-848delY-GFP was trapped in the chromatin
fraction by talazoparib, but to a lesser extent than WT PARP1-
GFP (Fig. 2e). Laser microirradiation assays conﬁrmed this partial
PARP1 trapping phenotype with the PARP1-848delY-GFP pro-
tein; whilst WT PARP1-GFP was rapidly recruited to the site of
microirradiation (peak ≈ 4 s) and induced PAR formation in a
similar time frame (Fig. 2f), the extent of PARP1-848delY-GFP
recruitment to the site of microirradiation was reduced, as was
PARylation (Fig. 2f). As a negative control, PARP1-N329Q-GFP
exhibited limited recruitment to damaged DNA (Fig. 2f). The
addition of talazoparib delayed PARP1-848delY-GFP dissociation
from microirradiated sites, but to a lesser extent than for WT
PARP1-GFP (Supplementary Figure 2e, f, p= 5 × 10−7, t-test).
PARP1-848delY-GFP also dissociated faster from microirradiated
sites, being absent from microirradiated regions 30 min after
microirradiation; WT PARP1-GFP still showed 40% of
maximal trapping at this timepoint (Supplementary Figure 2f,
Fig. 1 A genome-wide CRISPR screen for PARP inhibitor resistance identiﬁes in-frame Parp1 mutants. a Experimental scheme. b Locations of Parp1 guide
RNA target sites in exon two of the mouse Parp1 gene. c Parp1 western blot of lysates from talazoparib-resistant clones identiﬁed in the CRISPR screen.
Individual clones are colour-coded according to sgRNA present (see key). Clones 1, 2, 6, 7, 9, 12 and 13 with Parp1 sgRNAs have lost Parp1 protein
expression, whilst Parp1 sgRNA clone 8 (BR8, *) has retained Parp1 expression. d Clone BR8 has an in-frame Parp1 deletion and a Parp1 substitution
mutation. Sanger sequencing trace of the Parp1 sgRNA target site is shown, illustrating a 3 bp deletion on both alleles and a heterozygous c.130T>A
substitution mutation (p.44F>I) close to the CRISPR PAM site. e Parp1 is not trapped in the chromatin fraction by PARP inhibitor in the BR8 clone. Western
blots illustrating Parp1 in the chromatin and nuclear soluble fractions of wild-type ES cells and Parp1 mutant BR8 cells exposed to talazoparib. Data shown
are representative of two experiments. f PARP1 protein with a p.[43delM;44F>I] mutation has impaired recruitment to damaged DNA and does not initiate
PAR synthesis at damaged DNA. Localisation of PARP1-GFP to damaged DNA was estimated by visualising GFP signal at the microirradiated spot, as was
the generation of PAR at the damaged site by use of a PAR-binding PBZ-mRuby2 probe (see schematic). The time course of PARP1-GFP and PBZ-mRuby2
signals from CAL51 PARP1–/– cells transfected with PARP1-GFP (top) and PARP1-p.[43delM;44F>I]-GFP (bottom) are shown. “Damage” denotes time at
which microirradiation was carried out. g, h Dose response curves illustrating that clone BR8 is resistant to both talazoparib (g) and olaparib (h). BR13 is an
ES cell mutant with no Parp1 protein expression (see panel c); a transposon-mutagenised, Parp1 null mutant7 is also shown (red). Clone BR8 vs. BR13 and
Parp1–/– transposon, p= ns, ANOVA. Parp1 mutant clones vs. wild-type cells, p < 0.0001, ANOVA. Mean of ﬁve replicates plotted, error bars show SD.
Surviving fractions were calculated relative to DMSO-exposed cells for each mutant
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p= 5.5 × 10−3, t-test). These data therefore suggested that even
the relatively subtle defect in trapping in the 848delY mutant
(Fig. 2e, f) might be sufﬁcient to cause PARPi resistance.
We mapped the residues affected by the mutations that we
observed onto a previously described crystal structure of PARP1-
ZnF domains 1 and 2 together with the WGR, regulatory and
catalytic domains13. We found that several of the PARPi
resistance-causing mutations affected amino-acid residues (D45,
H742, D743 and E688) involved in hydrogen-bonding interac-
tions that bridge the DNA-binding domain and the catalytic
domain (Fig. 2g), suggesting that these might control inter-
domain interactions that mediate PARP1 trapping; similar inter-
domain domain interactions link DNA binding to activation of
PARP1 catalytic activity11–13. Taken together, these data
established that mutations outside of the DNA-binding domain
can cause PARPi resistance, likely by impairing PARP1 trapping.
PARP1 mutations cause PARPi resistance in BRCA1 mutant
cells. We next assessed whether PARP1 mutations could cause
PARPi resistance in a clinically relevant setting, such as in BRCA1
mutant tumour cells. Complete loss of both PARP1 and BRCA1 is
expected to be synthetic lethal1, 2. However, a growing body of
evidence suggests that many pathogenic BRCA1 mutations may
not result in complete loss of function. For example, SUM149
(also known as SUM149PT) triple-negative breast tumour cells
possess a commonly occurring hypomorphic BRCA1 exon
11 c.2288delT frameshift mutation and loss of the WT BRCA1
allele23. As a consequence, SUM149 cells do not express the full-
length BRCA1 p220 protein, but do express a hypomorphic splice
variant of BRCA1, Δ11b, which excludes the c.2288delT pre-
mature truncating mutation (along with most of the exon 11
coding sequence), but has some residual function24, 25. We and
others have previously conﬁrmed that the BRCA1 mutation in
SUM149 cells causes sensitivity to PARPi by demonstrating that
genetic reversion of the BRCA1 mutation in SUM149 cells via
CRISPR-Cas9 mutagenesis imparts PARPi resistance25, 26.
We carried out a genome-wide PARPi resistance CRISPR-Cas9
screen in SUM149 cells, using a previously validated sgRNA
library27, similar to our earlier screen in mouse ES cells. Out of 12
talazoparib-resistant clones analysed, 8 possessed one of three
PARP1 sgRNAs (Table 2), suggesting that talazoparib cytotoxicity
is mediated by PARP1 even in this BRCA1 mutant cell line. To
conﬁrm this observation, we infected Cas9-expressing SUM149
cells with a lentiviral sgRNA vector targeting the PARP1 coding
sequence homologous to the p.43/44 mutation site in the PARPi-
resistant mouse ES cell BR8 clone we identiﬁed earlier (Fig. 1d).
This sgRNA induced talazoparib resistance (Fig. 3a). We
subcloned two daughter clones from the PARPi-resistant
SUM149 population, TR1 and TR2; TR1 had four different
PARP1 alleles with frameshift mutations and lacked PARP1
protein expression, whilst TR2 expressed apparently full-length
PARP1 protein (Fig. 3b and Supplementary Data 4). TR2
possessed three different PARP1 alleles with frameshift mutations
(Table 3 and Supplementary Data 4) but also a p.43_45delMFD
in-frame deletion, similar to the p.43/44 mutations identiﬁed in
PARPi-resistant BR8 mouse ES cells (Fig. 1d). This supported the
hypothesis that the p.43delM mutation identiﬁed in the mouse
BR8 clone (Fig. 1d) was likely to be the cause of PARPi resistance,
as opposed to a passenger effect that co-occurred in a clone with a
non-PARP1-mediated mechanism of resistance. No PARP1 WT
DNA-sequencing reads were identiﬁed among subcloned PARP1
PCR products from either TR1 or TR2 (Supplementary Data 4).
The allele frequencies of the PARP1 mutations in TR1 and
TR2 suggested that there were ﬁve copies of the PARP1 locus in
SUM149 cells, conﬁrmed by single-nucleotide polymorphism
genotyping of SUM149 (Supplementary Data 4; A. Grigoriadis,
personal communication). Both clones remained talazoparib-
resistant after culture in the absence of PARPi, demonstrating
that this was a stably acquired phenotype (Fig. 3c, ANOVA, p <
0.0001). We did not ﬁnd evidence for other known mechanisms
of PARPi resistance in TR1 and TR2, such as reversion of full-
length BRCA1 expression28 (Supplementary Figure 3a), 53BP1 or
REV7 (MAD2L2) loss29 (Supplementary Figure 3b, c), or an
increase in DNA damage-induced nuclear RAD51 foci (Supple-
mentary Figure 3d). This suggested that PARP1 mutation or loss
could not only be tolerated in SUM149 cells but also caused
PARPi resistance.
By generating a series of isogenic SUM149 daughter clones
with different mechanisms of PARPi resistance (PARP1mutation,
BRCA1 reversion, deleterious TP53BP1 or REV7 (MAD2L2)
mutation28–32; Supplementary Figure 4a), we also found that
SUM149 cells with PARP1 mutations exhibited a comparable, if
not greater, level of PARPi resistance than previously identiﬁed
mechanisms of resistance (Supplementary Figure 4b, c; p <
0.0001, ANOVA compared to parental cells for all mutants).
PARP1 mutant SUM149 cells had the most profound PARPi-
resistant phenotype seen amongst 38 molecularly diverse breast
tumour cell lines (Supplementary Figure 5). We also found that
PARP1 mutant SUM149 cells did not exhibit cross-resistance to
cisplatin that might be expected if BRCA1 function had been
restored in these cells26 (Supplementary Figure 6a); in compar-
ison, 53BP1 mutant clones had an intermediate level of resistance
to cisplatin (p < 0.0001, ANOVA), as previously described29, as
did clones with a BRCA1 reversion, whilst REV7 mutants
Table 1 Results of sequencing sgRNA PCR products from
talazoparib-resistant mouse ES cell clones isolated from the
CRISPR screen described in Fig. 1a
Clone Likely cause of
resistance
Clonal with sgRNAs identiﬁed
BR1 Parp1 7 Parp1 (#1), Tmed5
BR2 Parp1 — Parp1 (#1)
BR3 — Gpd2
BR4 — Tbx20, Gpr89, Pde4d,
Arhgap12
BR5 21 Trp53, Csmd1
BR6 Parp1 — Parp1 (#2), Apol6
BR7 Parp1 12,1 Parp1 (#1), Abca14, Dtnb,
Tmed5
BR8 Parp1 #2 — Parp1 (#2), Lemd1, Slmo1
BR9 Parp1 #2 — Parp1 (#2)
BR10 Parp1 — Parp1 (#1), Spock1, P2ry6,
AW209491
BR11 Tdg 14 Tdg, Gm5597
BR12 Parp1 (by clonality) 7 Abca14, Dtnb
BR13 Parp1 — Parp1 (#1), Nwd1, Scn10a
BR14 Tdg 11 Tdg, Gm5597, Tmed5
BR15 — ND
BR16 — Defb25
BR17 — ND
BR18 — Traf3ip1, Hkdc1, Gm4876
BR19 — Dnajb11, Scaf8, Acbd3,
Msh2
BR20 — ND
BR21 5 Trp53, Csmd3, Chst15
BR22 — Cyp2r1, Tmem69
BR23 — ND
BR24 Tdg — Tdg
Where clonality can be inferred from the combination of different guides observed, this is shown
in column three
ND not determined (failure of PCR and/or sequencing)
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exhibited enhanced sensitivity to cisplatin (p < 0.0001, ANOVA),
a possible consequence of losing REV7’s role in translesion
synthesis33 (Supplementary Figure 6a). PARP1 mutation in
SUM149 cells enhanced the existing topoisomerase I inhibitor
sensitivity caused by BRCA1 mutation (Supplementary Figure
6b–d, p < 0.0001, ANOVA), consistent with the enhanced
camptothecin sensitivity caused by Parp1 mutation in mouse
ES cells (Supplementary Figure 1a) and previous
observations19, 20. These observations suggested that PARP1
mutation in BRCA1 mutant tumour cells caused a similar extent
of PARPi resistance as for known mechanisms of resistance, but
had differing effects on platinum sensitivity.
To assess whether the PARPi-resistant phenotype caused by
PARP1 mutation might also operate in vivo, we injected
SUM149-Cas9 and PARP1 mutant SUM149-TR2 cells subcuta-
neously in BALB/c nude mice. Once tumours had established, we
randomised mice into one of two treatment cohorts, one treated
with the clinical PARPi talazoparib and the other with the drug
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vehicle alone. Whilst talazoparib treatment delayed the growth of
SUM149-Cas9 xenografts and extended the survival of xenograft-
bearing mice, compared to vehicle treatment (p= 0.0086, log-
rank test, Fig. 3d), it did not have any detectable effect in mice
bearing PARP1 mutant SUM149-TR2 xenografts (p= 0.98, log-
rank test).
Residual BRCA1 function supports PARP1 loss in tumour cells.
We also found that PARP1 sgRNA caused PARPi resistance in
BRCA1 mutant COV362 ovarian tumour cells34 (BRCA1 c.2611fs
[exon 11] and c.4095+1G>T [exon 11 splice donor]), suggesting
that these observations were not private to SUM149 cells.
COV362 cells were infected with six different pools of lentiviral
PARP1 sgRNAs as used in the HeLa screen above (Fig. 2) and
selected in talazoparib. We found profound talazoparib resistance
in all sgRNA lentivirus-infected populations, except those infec-
ted with PARP1 sgRNA pool six, where resistance was less-pro-
nounced, although still signiﬁcant (Fig. 3e; p < 0.0001 in each
case, ANOVA compared to parental COV362-Cas9 cells). We
also isolated a number of daughter clones from the PARPi-
resistant COV362 populations. Some of these clones had lost
PARP1 expression while others had in-frame indels in PARP1,
including a clone with a p.119delKS mutation and three inde-
pendently derived clones all with p.848delY/p.848_849delYK
compound mutations (referred to as p.848delY/YK, Supplemen-
tary Figure 7a and Table 3). All clones with PARP1 mutations
remained resistant to talazoparib after culture without PARPi
selection during subcloning and expansion (Supplementary Fig-
ure 7b, c). Interestingly, COV362 clones isolated with Y848
mutations at the endogenous PARP1 locus (p.848delY/delYK)
showed a less-pronounced resistance phenotype compared to
complete null clones, although the extent of resistance was still
signiﬁcant compared to WT cells (Supplementary Figure 7b, c, d;
p < 0.0001, ANOVA). These clones also showed some residual
PARylation activity in agreement with the microirradiation
phenotype observed earlier (Supplementary Figure 7e and
Fig. 2f), suggesting an intermediate level of PARPi resistance
could be caused by a partial PARP1 trapping defect.
We also attempted to isolate PARP1 mutants from MDA-MB-
436 cells, which have a BRCA1 c.5396+1G>A mutation in the
splice donor site of exon 20. This mutation results in a truncated
BRCA1 protein lacking the BRCT region required for HR23, 35.
We were unable to isolate long-term talazoparib-resistant cells
from this cell line after transfection with PARP1 sgRNA-
expressing lentiviral pools. Analysis of cells grown in talazoparib
for a short period (Supplementary Figure 7f) showed that
mutations were induced at the sgRNA target sites, but cells with
PARP1 mutations did not survive in the long term (Supplemen-
tary Figure 7g). In contrast, sequencing of COV362 cells infected
with the same PARP1 sgRNA pools revealed that several pools of
talazoparib-resistant cells generated in the same way had
mutagenized all PARP1 alleles in all cells, indicated by very low
or absent WT reads (Fig. 3e and Supplementary Figure 7g). This
suggested that mutation of all PARP1 alleles was not tolerated in
MDA-MB-436 cells, in contrast to SUM149 or COV362 cells.
We therefore considered it possible that the residual BRCA1
function in SUM149 and COV362 might allow these cells to
tolerate PARP1 mutations. To address this, we inhibited the
residual BRCA1 function in SUM149 and COV362 cells with
siRNA targeting BRCA1 target sites outside exon 11; doing the
same in SUM149/COV362 PARP1 mutants isolated earlier
demonstrated that BRCA1 siRNA had a more profound cell
inhibitory effect in PARP1 mutant COV362 and SUM149 cells,
than in PARP1 WT parental cells (Fig. 3f–h, p < 0.05 for all cases
compared to parental cells, t-test). This suggested that some
residual BRCA1 function might exist in these cells and is required
for cell survival in the face of PARP1 mutation. BRCA2 siRNA
also selectively targeted PARP1 mutant COV362 and SUM149
cells, suggesting some requirement for BRCA2 function in these
cells despite the BRCA1 mutation (Fig. 3f–h, p < 0.05, t-test).
Taken together, these observations suggested that PARP1 loss
might be tolerated in COV362 and SUM149 cells due to some
residual BRCA1-dependent function. Exon 11 frameshift muta-
tions comprise approximately 30% of pathogenic BRCA1
mutations identiﬁed to date25, 36–39 and thus PARP1 mutation
and/or loss could be a clinically relevant mechanism of PARPi
resistance in this speciﬁc context.
A dense CRISPR screen for functional annotation of PARP1.
To investigate which functions of PARP1 were important for
cytotoxicity of talazoparib in BRCA1 mutant cells, we designed a
new tiling CRISPR library, comprising 489 guides, designed to
give the densest possible coverage of PARP1 mutations
Fig. 2 A focused CRISPR-Cas9 mutagenesis “tag, mutate and enrich” screen identiﬁes PARP1 mutations outside the DNA-binding domain that cause PARP
inhibitor resistance. a Experimental “tag, mutate and enrich” scheme to isolate missense and in-frame PARP1 mutants associated with PARP inhibitor
resistance. b Translated alignment of PARP1 amino-acid mutations identiﬁed in talazoparib-resistant cells isolated from lentiviral sgRNA pool 1 (designed to
target ZnF1 and ZnF2 domains) from the screen shown in a. By comparing the multiple different mutations isolated from pool 1, a PARP1 p.119_120delKS
minimal mutation associated with resistance was identiﬁed. Some insertions and larger deletions are omitted for clarity (see Supplementary Data 2). c
PARP1 p.119_120delKS mutation abolishes recruitment of a PARP1-GFP fusion to sites of microirradiated DNA damage. CAL51 PARP1–/– cells were
transfected with a wild-type PARP1-GFP cDNA construct or a PARP1 p.119_120delKS-GFP fusion cDNA expression construct and then exposed to localised
ionising radiation (a microirradiated spot) as in f. Time course of PARP1-GFP signal at microirradiated site is shown. d Location of three mutations
associated with PARPi resistance on a model of the PARP1 DNA structure12. e PARP1-N329Q and HD742F mutations ablate PARP1 trapping, while 848delY
partially reduces trapping. Western blot from PARP1 trapping assay for three PARP1-GFP mutants and wild-type PARP1-GFP is shown. MMS-treated cells
were lysed and fractionated into nuclear soluble (NS) and chromatin (C) fractions as described in Methods. Blot was probed with an anti-GFP antibody. f
PARP1-848delY mutation alters PARP1 localisation kinetics at sites of DNA damage. Microirradiation and PAR synthesis phenotypes of N329Q and
848delY PARP1 mutants. Green—PARP1-GFP signal, red—PAR sensor (PBZ-mRuby2). Note lower recruitment relative to wild type of both mutants, but
retention of PAR synthesis in 848delY. g Model of intramolecular communication between the DNA-binding ZnF1 domain and the catalytic (CAT) domain
based on mutants identiﬁed from screens. (1) 45delD mutation in ﬁrst zinc ﬁnger, (2) HD742F mutation shown in d, (3) E688 (Supplementary Data 2)
Table 2 sgRNA sequences identiﬁed in talazoparib-resistant
SUM149-Cas9 cells mutagenized with a genome-wide
CRISPR library
sgRNA Colonies
PARP1_ex16 5
PARP1_ex19 1
PARP1_ex22 1
PARP1_ex19, MCF2L_ex2 1
PARP1_ex22, JPH4_ex3 1
RABGAP1_ex8 1
ND (>2 guides) 2
12
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03917-2 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1849 | DOI: 10.1038/s41467-018-03917-2 | www.nature.com/naturecommunications 7
(Supplementary Data 5 and Fig. 4a) and carried out a tiling screen
in SUM149 cells in which the endogenous PARP1 locus had been
tagged with a C-terminal GFP coding sequence using the CRIS-
Paint system40. After mutagenesis followed by talazoparib selec-
tion and sorting GFP-positive cells as before, we sequenced the
PARP1 coding sequence from GFP cDNA using a panel of 15
amplicons (Supplementary Data 6). This screen further
illuminated the roles of different areas of PARP1 in PARPi
toxicity. In agreement with our previous results, a large number
of mutations were isolated which affected residues associated with
either direct DNA binding (Fig. 4b, c; Supplementary Data 7) or
the interfaces between ZnF domains (Fig. 4d). We also observed a
high density of mutations associated with PARPi resistance
affecting the WGR domain (Fig. 4b, e). Based on our previous
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screen, we hypothesised that points of contact of the WGR
domain with the ZnF and HD (regulatory) domains might be
important for PARPi resistance and PARP1 function and acti-
vation (Fig. 2f); in this new screen we identiﬁed several mutation
clusters at these points of contact (Fig. 4b, e; Supplementary
Figure 8a) supporting this hypothesis. Although we identiﬁed few
mutations in the catalytic domain that caused PARPi resistance—
perhaps because mutations directly disrupting the catalytic
activity would cause constitutive trapping and cytotoxicity—the
most frequent mutation in the catalytic domain isolated in the
screen affected residue A925, which is juxtaposed with residue
Y848 in the three-dimensional structure of PARP1, further sug-
gesting an important role for this region of the catalytic domain
in PARPi cytotoxicity (Fig. 4e, inset 2). The relative lack of
mutations in the BRCT domain, despite ample sequencing and
sgRNA coverage in this area (Fig. 4c and Supplementary Fig-
ure 8b) might indicate that this region is dispensable for PARPi
cytotoxicity and trapping.
PARP1 mutation observed in an olaparib-resistant patient. In
parallel with these genetic studies, we identiﬁed a PARP1 p.R591C
mutation (c.1771C>T) in an ovarian cancer patient who showed
de novo resistance to olaparib. The R591C mutation affects the
WGR domain at the point of contact with D45 and the HD
domain; our model (Fig. 2g) and previous work11–13 predict that
this would be a critical residue for inter-domain communication
in PARP1, between the DNA-binding and catalytic domains,
implying that this mutant might bind DNA but would not show
trapping. To investigate this, we assessed the recruitment of a
PARP1-R591C-GFP fusion protein to sites of microirradiation in
the presence and absence of the PARPi talazoparib. We found
that whilst PARP1-R591C-GFP was recruited to sites of micro-
irradiation, its dissociation from these sites was rapid compared
to WT PARP1-GFP; furthermore, PARP1-R591C-GFP was not
trapped on DNA by talazoparib, unlike WT PARP1-GFP
(Fig. 4f).
Discussion
A key observation that contributed to the trapping hypothesis of
PARPi cytotoxicity is that in HR proﬁcient cells, PARP1 itself is
required for cytotoxicty6, 7. Our genome-wide CRISPR screen
revealed that point mutations in the ZnF domains that abolish
DNA binding were sufﬁcient for this resistance, providing direct
genetic evidence for the trapping hypothesis.
Our genetic screens also uncovered several clusters of muta-
tions that suggest that regions of PARP1 outside the DNA-
binding domain can inﬂuence trapping (Figs. 2d and 4b),
observations that are consistent with inter-domain interactions
being critical for PARP1 binding and activation11–13. These
observations are also supported by an orthogonal approach using
ethyl methyl sulfonate mutagenesis screens in haploid cells41.
These observations add weight to the “reverse allostery”
hypothesis proposed by Murai et al.6, which suggests that PARPi
binding to the catalytic domain of PARP1 allosterically inﬂuences
interactions between DNA and the N-terminal DNA-binding
domains of the protein, to the extent that PARP1 becomes
trapped on DNA. It is possible that the PARP1 mutations we have
identiﬁed here are in amino-acid residues critical to this reverse
allosteric process and therefore prevent allosteric enhancement of
DNA binding upon inhibitor binding.
We also isolated a PARP1 mutant, p.848delY, which was
associated with PARPi resistance despite exhibiting some residual
PARP1 trapping. This reduced level of trapping might be sufﬁ-
cient to cause resistance—the amount of trapped PARP1 required
to induce cytotoxicity is not known. Nor is it known whether all
trapping, as observed by chromatin fractionation assays in the
presence of alkylating agents, is equal with respect to cytotoxicity
—PARP1 trapping at certain sites or lesion types may be more
toxic than at others. It is possible that Tdg is a source of such
lesions in ES cells, as loss of this speciﬁc glycosylase was sufﬁcient
for pronounced PARPi resistance (Supplementary Figure 1d).
Alternatively, it is possible that PARP1 trapping is not, in itself,
sufﬁcient for cytotoxicity and other factors altered by the muta-
tions are also required. For example, the Y848 residue is part of a
solvent-exposed helix in PARP1 that may participate in
protein–protein interactions—for example, with Timeless42, 43—
that could be important for generating a DNA lesion that is
cytotoxic. Mutations in another residue (A925) juxtaposed with
Y848 in the PARP1 tertiary structure also led to PARPi resistance,
possibly via a similar mechanism (Fig. 4e). It is possible that a
larger trapped complex of PARP1 and interacting partner(s) is
responsible for cytotoxicity, or that trapped PARP1848delY is
altered in such a way as to not be cytotoxic. Nevertheless, the
resistance phenotype of cells with mutations affecting Y848 at the
endogenous PARP1 locus is slightly less-pronounced than a
complete PARP1 knockout (Supplementary Figure 7d), sup-
porting the hypothesis that the residual PARP1 trapping corre-
sponds to some residual PARPi cytotoxicity. It will be interesting
to study this region further to pinpoint the cause of the reduced
cytotoxicity.
Our experiments also showed that PARP1 mutation can be
tolerated in certain BRCA1 mutant, PARPi-sensitive tumour cells.
This suggests that PARP1 trapping still underlies the increased
cytotoxicity of PARPi in these tumour cells but that some residual
BRCA1 function allows these cells to tolerate PARP1 mutations
(Fig. 3f–h), consistent with previous observations that some
Fig. 3 PARP1 mediates PARPi sensitivity in BRCA1 mutant cell lines. a Cas9-expressing BRCA1 mutant SUM149 cells were transduced with PARP1-ZnF or
hsvTK (non-targeting control) lentiviral sgRNA particles, selected in puromycin and exposed to the indicated talazoparib concentrations for 7 days.
Representative SRB-stained 24-well plate image is shown. bWestern blot showing PARP1 expression in talazoparib-resistant SUM149 clones TR1 and TR2.
Par, parental SUM149 cells. TR2 has an in-frame PARP1-p.43_45delMFD mutation. c SUM149 clones TR1 and TR2 are highly talazoparib-resistant. Plot
shows survival relative to DMSO-exposed cells after exposure to the indicated concentration of talazoparib for 7 days. Mean of ﬁve replicates plotted, error
bars show SD. d PARP1 mutant SUM149-TR2 xenografts do not respond to talazoparib treatment, whereas PARP1 wild-type SUM149 xenografts do. Top
panels show Kaplan–Meier survival curves, with a tumour volume of 1000mm3 (after which mice were sacriﬁced) used as a surrogate end point. Lower
panels show volume of individual tumours, normalised according to tumour volume on the day of randomisation (indicated by the arrow). e Pools of PARP1
guides cause talazoparib resistance in the BRCA1 mutant ovarian cancer cell line COV362. Cas9-expressing COV362 cells were transduced with the
indicated lentiviral guide pool, selected in puromycin and assayed as in c. f Silencing of residual BRCA1 function, or BRCA2, induces synthetic lethality with
PARP1 genetic loss in SUM149 cells. B1.S* is a SUM149 derivative with a secondary BRCA1mutation that confers PARP inhibitor resistance. SRB-stained 24-
well plate image is shown, 7 days after siRNA transfection. g Colony forming assay using SUM149-Cas9 parental cells and the talazoparib-resistant
daughter clone, TR2. Cells were transfected as in f, plated on 6-well plates and colonies stained and counted 2 weeks later. siRNA targeting BRCA1 or
BRCA2 signiﬁcantly reduces survival in PARP1 mutant cells (TR2) compared to the parental SUM149 line (t-test). h BRCA1 and BRCA2 silencing is also
synthetically lethal in COV362 PARP1 mutant clones A4 (p.119_120delKS) and D1 (p.848delY/YK). Colony formation assay as in g, p values for t-test
shown. Mean of three replicates plotted, error bars show SD
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BRCA1 exon 11 mutations do not result in complete loss of
BRCA1 function24, 25. Since PARP1;BRCA1 double-mutant cells
show distinct drug sensitivities compared to cells that become
PARPi resistant via other mechanisms, knowledge of the
mechanism of resistance in patients that relapse could inform the
best subsequent treatment. Importantly, we also observed a
PARP1 mutation that abolished trapping (R591C, Fig. 4f) in a
patient with de novo resistance to olaparib, suggesting that such
mutations can arise in patients and could potentially contribute to
resistance. It also seems reasonable to think that PARPi resistance
in some patients might display some level of heterogeneity, with
multiple different PARPi subclones emerging with distinct
mechanisms of resistance; recent advances in the genomic pro-
ﬁling of both solid and liquid biopsies derived from PARPi-
resistant patients44–46 might potentially assess whether this is the
case. Whether this turns out to be the case or not, our observation
that PARPi-resistant cells with different mechanisms of resistance
display different chemotherapy sensitivities (Supplementary Fig-
ure 6) suggests that deﬁning the molecular features of PARPi-
resistant disease biopsies might be important to determine the
best course of subsequent treatment.
The “tag-mutate-enrich” approach we have used, where the
tagging of genes with C-terminal GFP coding sequences (or other
selectable genes) followed by the targeted mutagenesis of these
genes via CRISPR-Cas9 mediated mutagenesis, allows, in prin-
ciple, full-length mutants of any gene of interest associated with a
selectable phenotype to be identiﬁed. This could be employed in
the analysis of other resistance mutations observed in patients
being treated with targeted therapies in order to annotate likely
drivers and passengers of resistance.
Methods
Cell lines. Mouse ES cells were cultured in Knockout DMEM containing 15% fetal
bovine serum (FBS) and leukaemia inhibitory factor as previously described47.
HeLa, CAL51 (source: DSMZ), COV362 (source: ECACC) and MDA-MB-436
(source: ATCC) cells were maintained in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% FBS (with 10 µg/ml insulin in the case of MDA-
MB-436). The HeLa cell line expressing PARP1-GFP gene from a bacterial artiﬁcial
chromosome has been previously described48. SUM149PT cells (referred to as
SUM149, source: Asterand Bioscience) were maintained in Ham’s F-12 medium
supplemented with 5% FBS, 10 µg/ml insulin and 1 µg/ml hydrocortisone.
All human cell line identities were conﬁrmed by STR typing and veriﬁed free of
mycoplasma infection using Lonza MycoAlert.
Genome-wide mouse CRISPR screen. We screened a previously described library
of mouse ES cells infected with a lentiviral single guide RNA (sgRNA) library
targeting 19,150 mouse genes (average ﬁve sgRNAs/gene)49. Two million CRISPR
mutagenised cells were exposed to a normally lethal concentration (25 nM) of the
clinical PARPi talazoparib17 (a.k.a. BMN 673; Fig. 1a) for 6 days and allowed to
form colonies. Colonies were picked and expanded in 96-well plates. sgRNA
sequences from resistant clones were ampliﬁed using U6-F and CRISPR-scaf-R
primers. Parp1 genotyping of resistant clones coming from the screen was done
with Parp1_CRISPRseq-F and Parp1_CRISPRseq-R primers (Supplementary
Data 8) using ReadyMix Taq polymerase (Sigma) and the following conditions: 94 °
C for 30 s; 30 cycles of 94 °C for 10 s; 56 °C for 10 s and 72 °C for 30 s; and the ﬁnal
extension, 72 °C for 4 min.
Genome-wide CRISPR screen in SUM149 cells. SUM149-Cas9 cells were gen-
erated by transduction of SUM149 cells with a Cas9-bsd lentivirus and selection in
7 µg/ml blasticidin. Cells were infected at multiplicity of infection (MOI) 0.3 with a
previously published genome-wide human lentiviral CRISPR library27. Cells were
selected with puromycin and then placed under talazoparib selection at a con-
centration that killed all non-infected SUM149 cells (100 nM). Twelve surviving
colonies were picked and analysed for the presence of sgRNA sequences by PCR
and Sanger sequencing as above.
Genetically engineered cell lines. CAL51 PARP1–/– cells were generated using the
Edit-R Gene Engineering System (GE Dharmacon). Cells were seeded at a density
of 1 × 105 cells/well in 24-well plates. After 24 h, cells were transfected with 1 µg
Edit-R CRISPR-Cas9 Nuclease Expression Plasmid mixed with 2.5 µl of 20 µM
PARP1 T2 crRNA (GACCACGACACCCAACCGGAGUUUUA-
GAGCUAUGCUGUUUUG) and 2.5 µl of tracrRNA (20 µM), using Lipofectamine
3000 according to the manufacturer’s instructions (Life Technologies). Four days
after transfection, cells were selected in 100 nM talazoparib for 5 days, and sur-
viving cells FACS-sorted into 96-well plates at one cell per well in drug-free
medium. After 2 weeks, the medium was changed to 100 nM talazoparib and cells
kept under selection for another month. Targeted genome modiﬁcations were
analysed by Sanger sequencing of PCR products cloned into pCR-TOPO-blunt
(Life Technologies). Ten individual colonies were sequenced. Clone T2.4, referred
to as CAL51 PARP1–/–, lacks PARP1 expression by western blot and has bi-allelic
out-of-frame deletions at the target site: a 50 bp deletion and a single base “C”
deletion, respectively.
Stable Cas9-expressing human cell lines were generated by transducing cells
with a Cas9-blasticidin lentivirus50 and selecting cells with integrated virus by
culturing in medium containing 7 µg/ml blasticidin.
SUM149 TR1 and TR2 were generated by infecting SUM149-Cas9-expressing
cells with a pLentiGuide-puro50 vector expressing an sgRNA targeting ZnF1
(Hs_PARP1_DBD_cr) and selecting cells with 100 nM talazoparib for 7 days.
Single cells were sorted using FACS and the resulting clones genotyped by PCR
with Hs_PARP1DBD-genoF and Hs_PARP1DBD-genoR primers (Supplementary
Data 8) using Q5 High-Fidelity DNA Polymerase (NEB) with the following
conditions: 98 °C for 30 s; 30 cycles of 98 °C for 10 s; 63 °C for 10 s and 72 °C for 30
s; and the ﬁnal extension, 72 °C for 2 min.
SUM149 PARP1-tagGFP2 cells were generated by CRISPaint40 using as a gene-
speciﬁc target sgRNA sequence 5′-GCAATTTTAAGACCTCCCTG-3′. GFP-
positive single-cell clones were isolated. They were genotyped with the
Hs_PARP1_intron22_F and tagGFP2_R primers (98 °C for 30 s, 30 cycles of 98 °C
for 10 s, 65 °C for 10 s and 72 °C for 30 s, and the ﬁnal extension, 72 °C for 2 min),
and the PCR product was Sanger sequenced to ensure a single in-frame integration.
Clones 5 and 8 originated from independent integration events.
Tdg mutant mouse ES cell clones were generated from JM8A3 (C57BL/6N)
cells47 by infection with a single lentivirus expressing a Tdg targeting sgRNA
(Tdg_gRNA) and Cas9 (lentiCRISPR51). Colonies were picked and genotyped by
PCR with Tdg_CR2_checkF and Tdg_CR2_checkR primers (Supplementary
Data 8) using ReadyMix Taq polymerase (Sigma) and the following conditions: 94 °
C for 30 s; 30 cycles of 94 °C for 10 s; 56 °C for 10 s and 72 °C for 30 s; and the ﬁnal
extension, 72 °C for 4 min.
Table 3 PARP1 mutations identiﬁed in talazoparib-resistant SUM149 and COV362 clones, determined by Sanger sequencing
Clone sgRNA PARP1 mutation(s)
SUM149 TR1 ZnF 1 Frameshift mutations: c.130_133delTTTG (p.[44delF;fs49*]), c.130_131delTT (p.44F>*), c.129_130delGT (p.43M>I*), c.121-
4_130_delCTAGTCGCCCATGTT [splice acceptor]
SUM149 TR2 ZnF 1 p.43delMFD and frameshift mutations: c.130_133delTTTG (p.[44delF;fs49*]), c.129_130insC (p.44F>L*), c.129delG
(p.43M>fs49*).
COV362 A4 Pool 2 p.119delKS
COV362 D1 Pool 5 p.848delY/848delYK
COV362 D4 Pool 5 p.848delYKPF
COV362 D8 Pool 5 Wild type
COV362 D9 Pool 5 p.848delY/848delYK
COV362 D11 Pool 5 p.848delY/848delYK
See also Supplementary Data 4 for more detail regarding SUM149 clones
fs frameshift resulting in the indicated number of different amino-acid residues
*Stop codon
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Fig. 4 A high-density tiling CRISPR-Cas9 screen enables functional annotation of a PARP1 mutation observed in an olaparib-resistant patient. a Positions of
sgRNA target sites in the dense PARP1 tiling library mapped onto the PARP1 coding DNA sequence shown in b. b Positions of mutations identiﬁed in the
dense PARP1 tiling screen. Number of mutant reads for in-frame mutant alleles affecting each base is shown on the y-axis normalised to per-base coverage
(mutant reads/total coverage × 1000). Only sites with coverage >500 reads are shown. The experiment was repeated in duplicate from two independently
tagged SUM149 PARP1-GFP cell lines (clone 5 and 8, shown in red and blue). Arrows highlight the mutations observed at inter-domain contacts as shown
in e. c Positions of protein domains mapped onto the PARP1 protein sequence. Red triangles indicate DNA–protein contacts based on crystal structures,
blue circles show the location of the patient mutation identiﬁed in this study. Grey arcs represent key inter-domain contacts as shown in e and Fig. 2g. d
Ribbon plot of ZnF1 and ZnF2 bound to a single-strand break (PDB: 2N8A). Ribbons are coloured red by residue based on the frequency of mutations
observed in the tiling screen affecting that residue as shown in b. The thickness of the ribbon is proportional to the frequency of mutations observed
affecting that residue. e Ribbon plot of the PARP1-DSB crystal structure (PDB: 4OQB) highlighting the clustering of mutations along the hydrogen-bonding
axis postulated in Fig. 2g and the A925 residue that abuts Y848 (inset 2). Regions marked 1 and 2 are magniﬁed. f Analysis of trapping for the R591C
patient mutation by microirradiation with or without talazoparib as shown. Although the R591C mutant can bind DNA at sites of damage (blue line), it is
not trapped in the presence of talazoparib (purple line)
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Reagents. Drugs, including olaparib and talazoparib, were purchased from Sell-
eckchem, except temozolomide and methyl methanesulfonate (Sigma-Aldrich).
Antibodies used are listed in Supplementary Data 9.
Cell viability and clonogenic assays. The viability of cells was measured after
5 days exposure to various concentrations of drugs using the Cell Titre-Glo assay
(Promega). Long-term drug exposure effects were assessed by colony formation
assay after 7–10 days exposure to a drug as described previously1, with drug-
containing medium refreshed weekly and cells stained at the end of the assay with
sulforhodamine B. When plotting survival curves, the surviving fraction was cal-
culated relative to DMSO (solvent)-exposed cells.
PARP1 sgRNA screen in HeLa cells. In all, 29 sgRNAs were designed using the
ChopChop algorithm52. The guides were synthesised and cloned in an array format
into pLentiGuide-puro50 by Euroﬁns genomics. A single colony for each vector was
used to inoculate a pooled culture for plasmid maxi prep (Qiagen). Six such pools
of vectors were packaged into viruses as previously described53. These pooled
viruses were used to infect HeLa PARP1-GFP/Cas9 cells. sgRNA-expressing cells
were enriched with a 3-day puromycin selection (3 µg/ml). The cells were subse-
quently incubated in 1 µM talazoparib for 12 additional days. The GFP-positive
population was enriched by cell sorting (BD FACSAria). Total RNA was extracted
from each of the six pools. One microgram of total RNA was converted to cDNA
with SuperScript III (ThermoFisher) and a GFP-speciﬁc primer (5′-
CCTTGATGCCGTTCTTCTGCTTG-3′), which allowed for ampliﬁcation only of
the target PARP1-GFP transcripts. Each of the six pooled cDNAs was ampliﬁed
with its corresponding Ion Torrent adapted primer pair ﬂanking the gRNA target
sites for that pool. This ampliﬁcation used Q5 High-Fidelity DNA Polymerase
(NEB) with the following PCR conditions: 98 °C for 30 s; 30 cycles of 98 °C for 10 s;
64 °C for 10 s and 72 °C for 30 s; and the ﬁnal extension, 72 °C for 2 min. Primer
sequences are provided in Supplementary Data 8.
PARP1 dense screen in SUM149 cells. A dense CRISPR library comprising 489
guides targeting PARP1 was synthesised (Twist Biosciences, Supplementary Data 4)
and cloned into the BbsI site of pKLV5-U6gRNA5-PGKPuroBFP27. One million
cells from each of two SUM149 PARP1-tagGFP2 clones were infected at MOI 0.3
as above and selected in puromycin. Cas9 was induced by treatment with dox-
ycycline for 2 days after which cells were replated and 100 nM talazoparib added.
cDNA was prepared using a GFP primer as above and 15 overlapping amplicons
prepared by PCR with Ion Torrent adapter tailed primers for genotyping (Sup-
plementary Data 5).
Sequencing and analysis. Puriﬁed RT-PCR products were mixed and sequenced
using the Ion Torrent PGM and a 318 chip with 850 ﬂows. Data were converted to
FASTQ format and aligned to the PARP1 cDNA sequence (ENST00000366794)
using Novoalign (Novocraft technologies). Mutations were called from the align-
ments using the Ensembl Variant Effect Predictor REST API54 (implementation:
github.com/GeneFunctionTeam/bioruby-sam-mutation). Sequences were also
translated and multiple alignments generated using Clustal Omega (http://www.
ebi.ac.uk/Tools/msa/clustalo/). For the dense screen, coverage was calculated per
base using samtools pileup (github.com/samtools, v1.5) with a maximum depth of
300,000.
Microirradiation assays. Cells were grown in glass-bottom culture dishes (MaTek,
P35G-0.170-14-C) in 10% FBS DMEM media and maintained at 37 °C and 5%
CO2 in an incubation chamber mounted on the microscope. Imaging was carried
out on Andor Revolution system, ×60 water objective with micropoint at 365 nm.
Only cells with similar GFP signal intensity were measured. The background
intensity (in the vicinity of the microirradiation area in the nucleus) was subtracted
from that at the microirradiation point and the maximum was normalised to 1.
Chromatin fractionation (trapping assay). The chromatin fractionation assay for
PARP trapping was based on a previously published protocol6. Cells were grown in
six-well plates, exposed for 1–4 h to 500 nM talazoparib and 0.01% MMS and
fractionated with the Subcellular Protein Fractionation kit for Cultured Cells
(ThermoFisher #78840) according to the manufacturer’s recommendations.
Equivalent volumes of each fraction were analysed by western blot using the
PARP1 (Cell Signaling #9542, rabbit), with TOP1 (BD #556597, mouse) or Histone
H3 (CST #9717, rabbit; low molecular weight region of blot probed separately) as
fractionation controls. Blots were imaged using the LiCor Odyssey multicolour
imaging system and secondary antibodies (Donkey anti-rabbit 680 and donkey
anti-mouse 800). Uncropped scans of western blots are shown in Supplementary
Figure 9.
Protein puriﬁcation. PARP1 point mutations were introduced in an isopropyl β-D-
1-thiogalactopyranoside (IPTG)-inducible C1-PARP1 plasmid (expressing His-
MBP-tagged human PARP1 cDNA) and transformed in Rosetta Escherichia coli
(Novagen). Cells were grown in terriﬁc broth at 37 °C until reaching OD600 1.0,
100 mM ZnSO4 was added and cells further grown to OD600 2.0. A unit of 0.5 mM
IPTG was added and cells were shaken at 18 °C overnight. Pellets were collected by
centrifugation and stored at −80 °C. Pellets were lysed (50 mM Tris-HCl (pH 7.5),
500 mM NaCl, 10 mM imidazole, 10 mM mercaptoethanol and protease inhibi-
tors), sonicated and cleared by centrifugation and 0.45 μm ﬁltration. The lysate was
passed through a 5 ml His Trap column (GE). The column was washed and bound
proteins eluted with a linear imidazole gradient. Pooled PARP1-containing frac-
tions were dialysed overnight (50 mM Tris-HCl (pH 7.5), 250 mM NaCl and 5 mM
mercaptoethanol) in the presence of MBP-TEV protease. Dialysed proteins were
cleared through 0.45 μm ﬁlter and cleaved MBP and MBP-TEV were removed
through another 5 ml His Trap column. Samples were loaded on a 5 ml HiTrap
Heparin column (GE) and eluted with a linear salt gradient. PARP1-containing
fractions were pooled, concentrated to 1 ml and injected on a HiLoad 16/600
Superdex 200 column (GE) equilibrated in 25 mM HEPES-NaOH (pH 7.5), 100
mM NaCl and 2 mM TCEP. PARP1-containing fractions were pooled, con-
centrated and snap-frozen in liquid N2.
PARylation assay. DNA dumbbell ligand (DB4) was prepared as previously
described12. In vitro PARylation reactions were carried out in a buffer (50mM
HEPES (pH 7.5), 150mM NaCl, 10mMMgCl2 and 1mM dithiothreitol) containing
100 nM PARP1 protein and 1 µM DB4. The reaction was started by the addition of
NAD+ to a 225 µM ﬁnal concentration (spiked with 5 µCi/ml 32P-NAD+) and
incubation at 30 °C. Aliquots were taken at various time points and the reaction was
stopped by the addition of 2× SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
loading dye and heat denaturation. Samples were resolved on SDS-PAGE, dried and
exposed on a phosphoimager plate (GE). Total radioactive intensity was quantiﬁed in
the lanes between the well start and the position of PARP1.
Xenograft experiment. Xenograft experiments were performed by Crown
Bioscience UK. Female BALB/c nude mice aged 6–8 weeks were purchased from
Envigo. Mice had access to irradiated G.19% extruded rodent diet from Harlan
Teklad (cat# 2919) throughout study. To form xenografts 5 × 106 cells were injected
subcutaneously into the left ﬂank with 1:1 (v/v) Matrigel as previously described17.
Tissue from established tumours was pooled and passaged with 25 µl Cultrex per
mouse to new hosts for the treatment study (100 mm3/mouse, n= 20/cell line).
Sample size was determined based on previous experience with this model system.
Mice were randomised when average tumour size reached 100 mm3, using the
multi-task method in the Studylog software, minimising differences in tumour
volume between groups. Talazoparib (0.66 mg/ml in DMSO) was diluted in diluent
(10% DMAc and 6% Solutol in phosphate-buffered saline) and administered orally
on a schedule of 3 days on, 4 days off. For the vehicle arm, an equivalent volume of
DMSO was diluted as above and administered on the same schedule. Tumour
volumes were estimated three times per week using the formula 0.5 × length ×
width2. For survival analysis, a ﬁnal tumour limit of 1000 mm3 was used. Blinding
was not used. Animal welfare for this study complies with the UK Animals Sci-
entiﬁc Procedures Act 1986 in line with Directive 2010/63/EU of the European
Parliament and the Council of 22 September 2010 on the protection of animals
used for scientiﬁc purposes. All experimental data management and reporting
procedures were in strict accordance with applicable Crown Bioscience UK
Guidelines and Standard Operating Procedures.
siRNA transfection. Lipofectamine RNAimax was used according to the manu-
facturer’s instructions (Invitrogen). Cells were transfected with Smart Pools tar-
geting the appropriate gene (GE Dharmacon).
Patient tumour sequencing. The PARP1:R591C mutation was identiﬁed in the
archival tumour sample of a 69-year-old patient (without a BRCA1 or BRCA2
germline mutation) with platinum-resistant high-grade serous ovarian cancer
enroled in a phase I trial of olaparib and durvalumab55 (NCT02484404). A panel of
cancer susceptibility and DNA repair genes (BROCA-HR56) was sequenced and the
PARP1:R591C mutation (genomic: chr1:226 564 979G>A) was identiﬁed at a var-
iant allele frequency (VAF) of 0.33 (65/198 reads). This ovarian carcinoma also had
a TP53 mutation (p.R196*) with VAF of 0.72. The patient did not have a response
to olaparib and durvalumab based on RECIST v1.1 criteria. The study has been
conducted in accordance with ethical principles that have their origin in the
Declaration of Helsinki and are consistent with the International Council on
Harmonization guidelines on Good Clinical Practice, all applicable laws and reg-
ulatory requirements, and all conditions required by a regulatory authority and/or
institutional review board. The study protocol was reviewed and approved by the
Institutional Review Board of the Center for Cancer Research, National Cancer
Institute. Written informed consent was obtained from all patients55.
Data availability. Data and cell lines are available from the authors on request.
Sequencing data are deposited at the ENA, accession number PRJEB24332.
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